UPDATE: Morgan Stanley Reiterates Overweight Rating, Removes PT on CVS/Caremark Corporation Following Acquisition of Coram

In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on

, but removed the $65.00 price target. In the report, Morgan Stanley noted, “CVS' $2.1 billion acquisition of Coram, Apria's home infusion business should help solidify CVS' position in the HC continuum and in enhancing its relationships with health systems and ACOs in our view. Importantly, we don't think deal stands in way of supply chain/sourcing partnership.” CVS/Caremark Corporation closed on Wednesday at $66.76.